This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, the programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. Over 650 delegates and over 100 presenting companies are expected.